Plain-English translation of NCT07168980 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a treatment plan that uses rituximab—an antibody medication that helps the immune system fight cancer cells—in higher amounts alongside intensive chemotherapy for children and adolescents with aggressive B-cell non-Hodgkin lymphoma and related blood cancers. The researchers hope that giving more doses of this medication earlier and more frequently will help more young patients survive and stay cancer-free longer than current treatment approaches.
Previous studies showed that this medication helped many patients, but some with more advanced or higher-risk cancers still had lower survival rates. Doctors believe that using the treatment more intensively and starting it earlier might help save more children's lives.
You likely qualify if…
You likely don't qualify if…
Depending on how advanced your cancer is, you will receive a series of chemotherapy courses (typically 3 to 8 courses) combined with multiple injections of rituximab given intravenously over several months. You will also receive preventive medication injected into the fluid around your spinal cord. Throughout treatment, you will have regular clinic visits for blood tests, physical exams, and imaging scans to monitor how well the treatment is working and to manage any side effects.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China